Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Pancreatin Powder is an approved biologic enzyme replacement therapy developed by Jinhua Enterprise (Ginwa) for the treatment of digestive disorders in children, particularly those associated with exocrine pancreatic insufficiency. Administered orally as a powder, the medication provides exogenous pancreatic enzymes—specifically lipase, amylase, and proteases—to assist in the hydrolysis and digestion of fats, carbohydrates, and proteins. This therapy is indicated for patients whose pancreas does not produce sufficient enzymes naturally, thereby facilitating proper nutrient breakdown and absorption in the gastrointestinal tract. It is commonly used to alleviate symptoms of indigestion and malabsorption in pediatric populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound Pancreatin Powder.